FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

贝伐单抗 福尔菲里 医学 伊立替康 氟尿嘧啶 奥沙利铂 内科学 结直肠癌 胃肠病学 中性粒细胞减少症 肿瘤科 外科 临床终点 化疗 癌症 随机对照试验
作者
Chiara Cremolini,Fotios Loupakis,Carlotta Antoniotti,Cristiana Lupi,Elisa Sensi,Sara Lonardi,Silvia Mezi,Gianluca Tomasello,M. Ronzoni,Alberto Zaniboni,Giuseppe Tonini,Chiara Carlomagno,Giacomo Allegrini,Silvana Chiara,Mauro D’Amico,Cristina Granetto,Marina Elena Cazzaniga,Luca Boni,Gabriella Fontanini,Alfredo Falcone
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:16 (13): 1306-1315 被引量:976
标识
DOI:10.1016/s1470-2045(15)00122-9
摘要

Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved progression-free survival of patients with metastatic colorectal cancer compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab. In this updated analysis, we aimed to provide mature results for overall survival—a secondary endpoint—and report treatment efficacy in RAS and BRAF molecular subgroups. Methods TRIBE was an open-label, multicentre, phase 3 randomised study of patients (aged 18–70 years with Eastern Cooperative Oncology Group [ECOG] performance status of 2 or less and aged 71–75 years with an ECOG performance status of 0) with unresectable metastatic colorectal cancer who were recruited from 34 Italian oncology units. Patients were randomly assigned (1:1) via a web-based procedure to receive FOLFIRI plus bevacizumab or FOLFOXIRI plus bevacizumab. Bevacizumab was given as a 5 mg/kg intravenous dose. FOLFIRI consisted of a 180 mg/m2 intravenous infusion of irinotecan for 60 min followed by a 200 mg/m2 intravenous infusion of leucovorin for 120 min, a 400 mg/m2 intravenous bolus of fluorouracil, and a 2400 mg/m2 continuous infusion of fluorouracil for 46 h. FOLFOXIRI consisted of a 165 mg/m2 intravenous infusion of irinotecan for 60 min, followed by an 85 mg/m2 intravenous infusion of oxaliplatin given concurrently with 200 mg/m2 leucovorin for 120 min, followed by a 3200 mg/m2 continuous infusion of fluorouracil for 48 h. Tissue samples for RAS and BRAF mutational status analyses were centrally collected. In this updated analysis, we assessed the secondary endpoint of overall survival in the main cohort and treatment efficacy in RAS and BRAF molecular subgroups. All analyses were by intention to treat. TRIBE was concluded on Nov 30, 2014. The trial is registered with ClinicalTrials.gov, number NCT00719797. Findings Between July 17, 2008, and May 31, 2011, 508 patients were randomly assigned. At a median follow-up of 48·1 months (IQR 41·7–55·6), median overall survival was 29·8 months (95% CI 26·0–34·3) in the FOLFOXIRI plus bevacizumab group compared with 25·8 months (22·5–29·1) in the FOLFIRI plus bevacizumab group (hazard ratio [HR] 0·80, 95% CI 0·65–0·98; p=0·03). Median overall survival was 37·1 months (95% CI 29·7–42·7) in the RAS and BRAF wild-type subgroup compared with 25·6 months (22·4–28·6) in the RAS-mutation-positive subgroup (HR 1·49, 95% CI 1·11–1·99) and 13·4 months (8·2–24·1) in the BRAF-mutation-positive subgroup (HR 2·79, 95% CI 1·75–4·46; likelihood-ratio test p<0·0001). Treatment effect was not significantly different across molecular subgroups (pinteraction=0·52). Interpretation FOLFOXIRI plus bevacizumab is a feasible treatment option for those patients who meet the inclusion criteria of the present study, irrespective of baseline clinical characteristics and RAS or BRAF mutational status. Funding GONO (Gruppo Oncologico del Nord Ovest) Cooperative Group and ARCO Foundation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
粉红大叔完成签到 ,获得积分10
刚刚
科研通AI2S应助研友_8QQlD8采纳,获得10
1秒前
1秒前
growl完成签到,获得积分10
1秒前
yuki完成签到,获得积分10
1秒前
1秒前
蕊蕊发布了新的文献求助10
1秒前
zhongxuejie完成签到,获得积分10
2秒前
核桃完成签到,获得积分0
3秒前
3秒前
3秒前
4秒前
善学以致用应助Shaynin采纳,获得10
4秒前
不爱吃西葫芦完成签到 ,获得积分10
4秒前
jiojiolq发布了新的文献求助20
4秒前
银包铜应助Ryan采纳,获得10
4秒前
4秒前
caisy完成签到,获得积分10
5秒前
易义德完成签到,获得积分10
5秒前
jokershy完成签到,获得积分10
6秒前
6秒前
6秒前
尤有发布了新的文献求助10
6秒前
一张发布了新的文献求助10
7秒前
yang完成签到,获得积分10
7秒前
追寻凌晴完成签到,获得积分10
8秒前
luha完成签到,获得积分10
8秒前
9秒前
YOOO发布了新的文献求助20
9秒前
dazhang15发布了新的文献求助30
9秒前
桐桐应助魁梧的曼凡采纳,获得10
9秒前
阳光的安南完成签到,获得积分10
10秒前
10秒前
10秒前
酷波er应助灰灰采纳,获得10
10秒前
忧心的洙完成签到,获得积分10
10秒前
刘恣含完成签到,获得积分10
10秒前
研友_LX7lK8完成签到 ,获得积分10
11秒前
11秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
徐淮辽南地区新元古代叠层石及生物地层 500
Robot-supported joining of reinforcement textiles with one-sided sewing heads 400
北师大毕业论文 基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 390
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4023306
求助须知:如何正确求助?哪些是违规求助? 3563350
关于积分的说明 11342113
捐赠科研通 3294890
什么是DOI,文献DOI怎么找? 1814795
邀请新用户注册赠送积分活动 889504
科研通“疑难数据库(出版商)”最低求助积分说明 812964